Molecular classification of aggressive B-cell lymphoma

Kamil Bojarczuk, Björn Chapuy

Department of Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany

Take home messages

- Sequencing-based approaches are readily used for molecular classifications of aggressive B-cell lymphomas.
- Genetic classifiers identify novel vulnerabilities and inform clinical trial designs.
- Genetically-distinct DLBCLs provide insights into unique lymphomagenesis, prognosis prediction and combination of targeted treatments.

Introduction

Large B-cell lymphomas (LBCLs) represent a molecularly and clinically heterogenous group of tumors that are thought to arise from antigen exposed B-cells which includes Burkitt Lymphoma (BL), Diffuse Large-B-cell Lymphoma (DLBCL), Primary Mediastinal Lymphoma (PMBL) and Primary Central Nervous System Lymphoma (PCNSL). The intrinsic heterogeneity of these tumors prompted the development of various classification schemes over the last decades and included molecular classifiers that (i) improved the accuracy of diagnosis; (ii) identified relevant molecular subtypes (iii) developed prognostic models for relevant clinical endpoints; and (iv) more recently stratified patients for disease management. Technical advantages paved the way for next generation sequencing (NGS)-based techniques to be included in clinical and/or low throughput-based molecular classifiers. Here, we summarize recent advances and highlight notable examples.

Current state-of-the art

Primary mediastinal lymphoma (PMBL)

PMBL was initially classified as a morphological subtype of DLBCL. Comparative whole transcriptome gene expression profiling highlighted similarities of PMBL with classical Hodgkin Lymphoma (cHL) and defined PMBL as a distinct WHO recognized entity. Subsequent genomic studies revealed also striking genetic similarities between PMBL and cHL, including 2p/REL and 9p24/JAK2/PD-L1/PD-L2 amplifications. Given the success of immune checkpoint blockade in cHL, the frequent 9p24/JAK2/PD-L1/PD-L2 gain inspired evaluation PD-1 blockade in PMBL with very good and durable responses that eventually led to FDA approval in 2018.

Primary central nervous system lymphoma (PCNSL) and primary testicular lymphoma (PTLs)

PCNSL and PTLs are primary extranodal LBCLs with inferior responses to current therapies. To identify targetable genetic lesions in these rare entities, we characterized somatic mutations, somatic copy number alterations (SCNAs) and structural variants (SVs), and compared them to genetic signatures of DLBCL and PMBL. These studies identified unique combinations of genetic alterations in discrete LBCL subtypes and subtype-selective bases for targeted therapy. PCNSLs and PTLs exhibited multiple genetic mechanisms (MYD88L265P mutations and NFKBIZgain) that led to near-uniform oncogenic Toll-like receptor (TLR) activation. Most PCNSLs also harbored co-occurring activating mutations in the proximal B-cell receptor (BCR) molecule, CD79B, suggesting clinical evaluation of targeted inhibitors of the BCR- and TLR-signaling pathways. Notably, PCNSLs and PTLs also shared frequent 9p24.1 genetic alterations with very good and durable responses to current treatments.

Transcriptional heterogeneity in DLBCL

DLBCL is the most common aggressive LBCL with cure rates in up to 65% of patients. The remainder eventually succumbs to their disease, highlighting the unmet clinical need to develop new treatment approaches for relapsed patients and to identify those patients that benefit/not benefit from current treatments.

Besides recognized morphological subtypes, DLBCLs is transcriptionally divided into activated B-cell (ABC) and germinal
center B-cell (GCB) subtypes. The distinction between GCB-, ABC-type and unclassifiable DLBCLs is based on whole transcriptome gene expression profiling. Subsequent efforts focused on capturing the complex transcriptional phenotype by more parsimonious assays, including easy to implement immunohistochemistry (IHC) or the more recently reported nanostring-based assays. IHC-based assays are extensively used in practice to date and consequently adopted for biomarker-driven studies, despite numerous issues that have been raised regarding its accuracy and reproducibility. Thus far, patient stratification for treatment based on transcriptional subtypes has been unsuccessful.

High grade lymphoma and double hit lymphoma

Recently, the WHO recognized a new provisional entity called “high grade lymphoma” that showed a blastoid morphology and/or is phenotypically an intermediate between BL and DLBCL. Many of these tumors exhibit juxtaposition of either BCL2, BCL6, or MYC to strong enhancer elements such as the Ig-enhancers (ie, “double or triple hits”). Notably, this genetic constellation also occurs in the absence of above morphological/phenotypical markers in DLBCL NOS underscoring that these category is a heterogeneous group of lymphomas of which some have unfavorable outcome following standard chemoimmunotherapy or after high-dose chemotherapy with autologous transplantation. Further work on larger cohorts is needed to clarify the biology of these lymphomas.

Genetic heterogeneity of DLBCL

The recognized clinical heterogeneity in DLBCL inspired the search for an underlying genetic heterogeneity. While initial studies were focused on the discovery of single genetic alterations, genome-wide technologies allowed for a more precise picture of the DLBCL genome. However, these studies were either limited by focusing on single alterations, low sample size or clinical annotation.

In order to overcome these limitations, we recently integrated recurrent mutations, SCNAS and SVs and discovered 5 distinct DLBCL subsets (Fig. 1), including: (1) a high-risk ABC DLBCLs with near-uniform BCL2 copy gain, frequent activating MYD88 and CD79B mutations and extranodal tropism (C5 DLBCLs); (2) previously unappreciated favorable-risk ABC-DLBCLs with genetic features of an extrafollicular, possibly marginal zone origin (C1 DLBCLs); (3) poor-risk GCB-DLBCLs with BCL2 SVs, inactivating mutations and/or copy loss of PTEN and alterations of epigenetic enzymes (C3 DLBCLs); (4) a newly defined group of good-risk GCB-DLBCLs with distinct alterations in BCR/PI3K, JAK/STAT and BRAF pathway components and multiple histones (C4 DLBCLs); and (5) an ABC/GCB-independent group of tumors with biallelic inactivation of TP53, 9p21.3/CDKN2A and
associated genomic instability (C2 DLBCLs). Importantly, these genetically defined subtypes provided new insights into the pathogenesis of these tumors, suggest novel rational combination therapies and predict outcome (Fig. 1). These results were largely confirmed by an independent non-overlapping large-scale study following a completely different analytical approach and that found similar groups with shared pathogenetic mechanisms. 19

Future perspectives

Current strategies for the treatment of DLBCL do not reflect the genomic complexity of the disease. At present, novel targeted agents are tested in unselected patients or those defined solely by clinical prognostic categories, such as the International Prognostic Index (IPI), or tumor transcriptional subgroups, GCB vs ABC. This approach has led to failed phase III trials of multiple targeted agents and uncertain prospects for others. We anticipate that the provided genomic framework will guide rational study design as recently exemplified in a preclinical model of C3 DLBCLs, that had long-term remission through a rational combination of BCL-2 and PI3Ka/b inhibitors. 20

References

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
2. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871–3879.
3. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–862.
4. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–3277.

*5. Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869–881.

Comparative analysis of somatic mutations, copy number alterations and structural variants highlighted shared genetic features of in PCNSL and PTL with DLBCL and PMBL, that can be targeted therapeutically.

6. Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130:267–270.
7. Naylor L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071–3073.
8. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:303–511.
9. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
10. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214–1217.
11. Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood. 2017;129:280–288.
12. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105:13520–13525.
13. Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large b cell lymphoma. Cancer Cell. 2012;22:359–372.
14. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43:830–837.
15. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
16. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109:3879–3884.

*17. Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481–494. e415.

Largest genomic study of clinically annotated cohort of 1001 DLBCL samples, focusing on mutation and copy number discovery in the known COO-framework.

18. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenetic mechanisms and outcomes. Nat Med. 2018;24:679–690.

Comprehensive genomic analysis of recurrent genetic alterations, including mutations, SCNAS and SVs. Through an unbiased integration 5 discrete and genetically distinct DLBCL subtypes were identified. These DLBCL subtypes provided insights into different pathogenetic mechanisms, which were predictive for outcome and suggest rational combination therapeutic strategies.

19. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:136–1407.

Comprehensive genomic identified recurrent mutations, SCNAS and SVs. Co-segregated genetic alterations were analysed in a COO framework, and four overlapping genetic clusters were identified, which shared features with the C1-C5 DLBCL subsets. Seeds to identify a cluster were in this study hand-selected and excluded SCNAS.

20. Bojarczuk K, Wienand K, Ryan JA, et al. Targeted inhibition of PI3Ka/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70–80.

Functional proof-of-concept study providing in vitro and in vivo evidence about synergy between PI3Ka/b inhibition and BCL-2 blockade in genetically defined DLBCL subtypes.